Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

One of the most notable accomplishments of the first Trump Administration was its willingness to take on the status quo of ...

Propel Health Communications, a 2025 MM+M Agency 100 honoree, hired Christopher Thorn as SVP, creative director and Lauren ...

The amount of frozen funds could be as high as $200 million, or potentially more than $300 million, according to two ...

Overall, the initial steps of the wind-down will result the in the cancellation of nearly $500 million. Not all mRNA related ...

It’s back-to-school season, which means parents are shuttling their kids to pediatricians for annual checkups — and advocates for and against states’ exemptions to vaccine mandates for school entry ...

Vertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into ...

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc. investors who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025.

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the ...

Asian markets closed mostly higher on Monday, with Japan's Nikkei 225 falling 1.25%, Hong Kong's Hang Seng gaining 0.92%, ...

Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE ...